e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 12

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

Magnus Lindskog; Anna Laurell; Anders Kjellman; Bohuslav Melichar; Pablo Maroto Rey; Henryk Zieliński; Felipe Villacampa; Pierre Bigot · 2022 · European Urology Open Science

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Background: The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations with immune checkpoint inhibitors. Innovative treatment options combining TKI and other immune-stimulating agents could prove beneficial. Objective: To evaluate the clinical effects on metastatic disease when two doses of allogeneic monocyte-derived dendritic cells (ilixadencel) are administrated intratumorally followed by nephrectomy and treatment with sunitinib compared

Abstract by Magnus Lindskog; Anna Laurell; Anders Kjellman; Bohuslav Melichar; Pablo Maroto Rey; Henryk Zieliński; Felipe Villacampa; Pierre Bigot, European Urology Open Science (2022) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.euros.2022.03.012